Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
作者： Katinka Albrecht , Angela Zink
DOI: 10.1186/S13075-017-1266-4
关键词:
摘要: Prognostic factors are used for treatment decisions in rheumatoid arthritis (RA). High disease activity, the early presence of erosions, and autoantibody positivity most frequently poor prognostic but other features, such as functional disability, extraarticular disease, or multibiomarkers, also assessed. incorporated current recommendations management RA inclusion criteria randomized controlled trials. They defined heterogeneously relevance a single combined remains unclear. This review summarizes definitions their use clinical research. Perspectives on future research outlined.
biomedcentral.com
springer.com
core.ac.uk
sci-hub.se 参考文章(49)
Nathan Vastesaeger, Stephen Xu, Daniel Aletaha, E. William St Clair, Josef S. Smolen, A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis Rheumatology. ,vol. 48, pp. 1114- 1121 ,(2009) , 10.1093/RHEUMATOLOGY/KEP155
Edward C. Keystone, Boulos Haraoui, Benoît Guérette, Neelufar Mozaffarian, Shufang Liu, Arthur Kavanaugh, Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study The Journal of Rheumatology. ,vol. 41, pp. 235- 243 ,(2014) , 10.3899/JRHEUM.121468
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald Van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna MW Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet Van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose Da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten De Wit, Désirée Van Der Heijde, None, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Annals of the Rheumatic Diseases. ,vol. 76, pp. 960- 977 ,(2014) , 10.1136/ANNRHEUMDIS-2016-210715
Raimon Sanmartí, Susana García-Rodríguez, José María Álvaro-Gracia, José Luis Andreu, Alejandro Balsa, Rafael Cáliz, Antonio Fernández-Nebro, Iván Ferraz-Amaro, Juan Jesús Gómez-Reino, Isidoro González-Álvaro, Emilio Martín-Mola, Víctor Manuel Martínez-Taboada, Ana M. Ortiz, Jesús Tornero, Sara Marsal, José Vicente Moreno-Muelas, 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatología Clínica. ,vol. 11, pp. 279- 294 ,(2015) , 10.1016/J.REUMAE.2015.05.002
Rachel Knevel, Gerður Gröndal, Tom W J Huizinga, A Willemien Visser, Helgi Jónsson, Arnór Víkingsson, Árni Jón Geirsson, Kristján Steinsson, Annette H M van der Helm-van Mil, Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study Annals of the Rheumatic Diseases. ,vol. 71, pp. 707- 709 ,(2012) , 10.1136/ANNRHEUMDIS-2011-200627
Bruno Fautrel, Benjamin Granger, Bernard Combe, Alain Saraux, Francis Guillemin, Xavier Le Loet, Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort Arthritis Research & Therapy. ,vol. 14, pp. 1- 9 ,(2012) , 10.1186/AR4092
Jeffrey R Curtis, Shuo Yang, Lang Chen, Grace S Park, Bojena Bitman, Brian Wang, Iris Navarro-Millan, Arthur Kavanaugh, Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial Annals of the Rheumatic Diseases. ,vol. 71, pp. 206- 212 ,(2012) , 10.1136/ARD.2011.153551
Jasvinder A. Singh, Kenneth G. Saag, S. Louis Bridges, Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H. Shmerling, Jeffrey R. Curtis, Daniel E. Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L. Matteson, John T. Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E. William St.Clair, Elizabeth Tindall, Amy S. Miller, Timothy McAlindon, 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Arthritis & Rheumatism. ,vol. 68, pp. 1- 26 ,(2016) , 10.1002/ART.39480
Iris M Markusse, Jeska K de Vries-Bouwstra, K Huub Han, Peter AHM van der Lubbe, Anne A Schouffoer, Pit JSM Kerstens, Willem F Lems, Tom WJ Huizinga, Cornelia F Allaart, Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis Arthritis Research & Therapy. ,vol. 16, pp. 430- 430 ,(2014) , 10.1186/S13075-014-0430-3
Elisa Gremese, Bruno Seriolo, Guido Valesini, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Carlo Salvarani, Marco Matucci-Cerinic, Serena Bugatti, Stefano Alivernini, Nicolo' Pipitone, Roberto Caporali, Serena Guiducci, Carlomaurizio Montecucco, Gianfranco Ferraccioli, Rossana Scrivo, Fabrizio Conti, Giuseppe Zampogna, Maurizio Cutolo, Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clinical and Experimental Rheumatology. ,vol. 29, pp. 7- 14 ,(2011)